Oliff H S, Marek P, Miyazaki B, Weber E
Department of Pharmacology, College of Medicine, University of California, Irvine 92717, USA.
Brain Res. 1996 Aug 26;731(1-2):208-12. doi: 10.1016/0006-8993(96)00582-3.
The present study was designed to evaluate whether the neuroprotective efficacy of MK-801 in focal cerebral ischemia was dependent on strain and/or vendor differences. MK-801 (0.12 mg/kg i.v. bolus followed by 0.108 mg/kg/h infusion or 0.60 mg/kg i.v. bolus followed by 0.540 mg/kg/h infusion) or saline was administered just after intraluminal middle cerebral artery occlusion. Administration of 0.540 mg/kg/h MK-801 provided strain/line-dependent neuroprotection in the following rank order: Simonsen Laboratories Sprague-Dawley rats > Simonsen Laboratories Wistar rats > Taconic Laboratories Sprague-Dawley rats. After 0.108 mg/kg/h MK-801 treatment, Simonsen Laboratories Wistar rats were the only strain/line that were significantly neuroprotected. These results indicate that the neuroprotective effect of an experimental drug may be influenced by rat strain and vendor differences.
本研究旨在评估MK-801对局灶性脑缺血的神经保护作用是否取决于品系和/或供应商差异。在大脑中动脉腔内闭塞后立即给予MK-801（静脉推注0.12mg/kg，随后以0.108mg/kg/h输注，或静脉推注0.60mg/kg，随后以0.540mg/kg/h输注）或生理盐水。给予0.540mg/kg/h的MK-801可提供品系/品系依赖性神经保护，其顺序如下：西蒙森实验室的斯普拉格-道利大鼠>西蒙森实验室的Wistar大鼠>塔科尼克实验室的斯普拉格-道利大鼠。在0.108mg/kg/h的MK-801治疗后，西蒙森实验室的Wistar大鼠是唯一有显著神经保护作用的品系/品系。这些结果表明，实验药物的神经保护作用可能受大鼠品系和供应商差异的影响。
